Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jan 22;16(1):e0245645. doi: 10.1371/journal.pone.0245645

The extraperitoneal French AmbUlatory cesarean section technique leads to improved pain scores and a faster maternal autonomy compared with the intraperitoneal Misgav Ladach technique: A prospective randomized controlled trial

Kaouther Dimassi 1,2,*, Ahmed Halouani 1,2, Amine Kammoun 1, Olivier Ami 3, Benedicte Simon 4, Luka Velemir 5, Denis Fauck 6, Amel Triki 1,2
Editor: Georg M Schmölzer7
PMCID: PMC7822305  PMID: 33481875

Abstract

Objective

To determine whether the French AmbUlatory Cesarean Section (FAUCS) technique reduces postoperative pain and promotes maternal autonomy compared with the Misgav Ladach cesarean section (MLCS) technique in elective conditions.

Study design

One hundred pregnant women were randomly, but in a non-blinded manner, assigned to undergo FAUCS or MLCS. The primary outcome was a postoperative mean pain score (PMPS), and secondary outcomes were a combined pain/medication score, time to regain autonomy, surgical duration, calculated blood loss, surgical complications, and neonatal outcome.

Results

Women in the FAUCS group experienced less pain than those in the MLCS group (PMPS = 1.87 [1.04–2.41] vs. 2.93 [2.46–3.75], respectively; p < 0.001). Six hours after surgery, the combined pain/medication score for FAUCS patients was 33% lower than that for MLCS patients (p < 0.001). FAUCS patients more rapidly regained autonomy, with 94% reaching autonomy within 12 h vs. 4% of MLCS patients (p < 0.001). There were no differences in maternal surgical or neonatal complications between groups.

Conclusions

Our results indicate that FAUCS can reduce postoperative pain and accelerate recovery, suggesting that this technique might be superior to MLCS and should be more widely used. One potentially key difference between FAUCS and MLCS is that MLCS includes 100 mcg spinal morphine anesthesia in addition to the same anesthesia used by FAUCS. Any interpretation of apparent differences must take the presence/absence of morphine into account.

Introduction

Cesarean section (CS) is the most common major obstetric surgery and the oldest operation in the field of abdominal surgery. Until the 17th century, CS was an exclusively lethal operation for the mother, performed to save or separate the newborn from a dead or dying mother [1,2]. Fortunately, improvements in obstetric surgical techniques based on modern scientific concepts were achieved at the end of the 20th century, leading to safer, simpler, and less traumatic approaches to CS [2]. In the 1990s, Stark introduced the Misgav Ladach cesarean section (MLCS) technique [3], also known as the Joel-Cohen technique, which became a widely-used standard for CS delivery in Tunisia and several European countries.

Recently, little progress has been made in the field of CS techniques. Twenty years after their invention, intraperitoneal CS techniques such as MLCS remain widely used [4]. Today, approximately 1 in 5 births worldwide is performed by CS due to various factors influencing medical decision-making [5] and their intuitive protective effect in cases of cephalopelvic dystocia [6]. However, CS techniques remain pathogenic and traumatic compared with vaginal delivery. Women who undergo CS frequently experience severe pain, feel disabled, and are unable to take care of themselves or their newborn in the first days after surgery, which affects maternal-infant bonding and the ability to lactate [7,8]. However, with advances in woman-centered perinatal care, a return to extraperitoneal approaches is regaining interest [9,10], because they are associated with less need for intravenous painkillers, shorter hospital stays, and earlier return to home, where breastfeeding can occur in a more comfortable environment.

In a retrospective analysis of over 3,000 cases, an innovative approach to CS known as the French AmbUlatory cesarean section (FAUCS) was found to enhance women’s recovery [9]. FAUCS differs from MLCS in several major ways. MLCS involves a horizontal opening of the aponeurosis and linea alba splitting on the median line, tearing of the peritoneum with fingers, and an intraperitoneal approach allowing air, blood, and amniotic fluid into the peritoneal cavity. Uterine suture is performed with a single-layered linear suture along the entire hysterotomy. In the FAUCS technique, however, only the anterior sheath of the aponeurosis is opened vertically on the left side, which is called a paramedian incision. Given no posterior sheath exists under Douglas’ line, the linea alba is respected. The approach is extraperitoneal on the left side of the bladder, and the hysterotomy is closed using a double-layered purse-string suture.

We introduced the FAUCS technique to our maternity department in January 2018 and demonstrated its safety in a previous study [4]. In the present study, we determined whether FAUCS reduces postoperative pain compared with MLCS without increasing intra- or postoperative complications in elective conditions.

Materials and methods

Ethics statement

This study was specifically approved by Mongi Slim University Hospital, La Marsa, Tunisia, local hospital ethics committee (approval number 05/2018) on March 5th, 2018 and written consent was obtained. Enrolment of the first patient started on August 1st 2018.

Because all protocols were originally written in French, this study was registered on clinicaltrials.org (NCT03741907) on November 15th 2018, after enrolment of participants started, due to administrative and english translation process delay, but registration at "clinicaltrials.gov" is not mandated by Tunisian law, which covered all legal aspects of this study. The full protocol is available on the clinicaltrials.gov site.

Data collection was conducted in compliance with Tunisian laws regarding personal data protection. The authors confirm that all ongoing and related trials for this procedure are registered.

Study design and participant selection

We performed an unblinded randomized clinical trial comparing MLCS versus FAUCS at Mongi Slim University Hospital, La Marsa, Tunisia, between August 2018 and March 2019. Women were included if they had a singleton term pregnancy delivered through a planned indicated CS. Women were excluded if their pregnancies involved known fetal, placental, or uterine anomalies.

All women who met the inclusion criteria, including being age 18–48 and gestational age 37 weeks, were invited to participate in the study during their final prenatal visit. Recruitment started on August 1st of 2018 and follow-up of the last enrolled patient ended on March 31st of 2019. Those providing written informed consent were consecutively included in a preliminary patient list managed by an investigator who was not involved in patient care. Before randomization, investigators excluded women who were initially recruited but had to undergo emergency surgery before the originally scheduled date (e.g., in cases of acute fetal compromise) or were operated on by a different surgeon than those assigned to the study. Women included in the study were provided a study number on their delivery day in chronological order. Random assignment to FAUCS or MLCS groups was performed by an investigator who was not involved in patient care using Kendall and Smith’s Tables of Random Sampling Numbers [11]. Subjects were assigned into 2 blocks of 50 subjects for randomization.

Surgical procedures and after-care

Participants, residents involved in patient care, and caregivers were blinded to the CS technique before the operation and were informed at discharge. Anesthetists and surgeons were informed of the CS technique on the due date in the operating room. No post-op caregivers and residents were present during the surgery.

The MLCS spinal anesthesia protocol included 7–10 mcg bupivacaine (depending on patient height), 100 mcg morphine, and 10 mcg sufentanil. The FAUCS spinal anesthesia protocol included 7–10 mg bupivacaine (depending on patient height), 10 mcg sufentanil, and no morphine.

All surgeries were performed by two senior surgeons, who performed the MLCS technique as described in 1999 [3] or the FAUCS technique as described in 2017 [9]. The main differences between FAUCS and MLCS concerned fascia incision, approach of the lower uterine segment, and uterine closure [4]. In the MLCS technique, tissues and fascia were spread apart ~2–3 centimeters at the midline, and the incision was further broadened with two fingers. The vertical rectus muscles were separated, and the peritoneum was opened transversely with fingers. The uterus was closed with a single-layer suture. In the FAUCS technique, only the anterior sheath of the aponeurosis was opened vertically on the left side, and the linea alba was respected. The approach was extraperitoneal on the left side of the bladder. The uterus was closed using a purse-string suture [4,9]. To ensure that the patients who had undergone FAUCS or MLCS were visually indistinguishable post-operation, a subcuticular absorbable Vicryl suture was employed for skin closure in both techniques.

Hematocrit levels were assessed before and after surgery. Analgesics were administered by nursing staff upon patient request via a visual analog scale (VAS) [12]. VAS is the most used scale for assessing level of post-operative patient pain. VAS assessments were made every 6 h: H0, H6, H12, H18, and H24. A standardized analgesic scheme was used: first line was intra-rectal 100 mg ketoprofen every 6 h; second line was intravenous 1 g paracetamol every 6 h, and third line was oral 50 mg tramadol every 6 h.

Women were encouraged to make an attempt to stand every hour after surgery. Normal oral food intake was initiated as soon as gas passage occurred and when the patient felt hungry. Women were evaluated 24 h after surgery. If there were no complications and if the patient felt autonomous and pain-free, she was discharged 24 h after surgery. In other cases, patients were discharged at least 48 h after surgery after a similar evaluation of maternal autonomy.

Study outcomes

The primary outcome measure was the postoperative mean pain score (PMPS), calculated as a mean of the five VAS scores performed at postoperative time points every 6 h over the course of 24 hours: H0 which designated the end of surgery time, H6, H12, H18 and H24.

Secondary outcome measures were as follows: (1) postoperative pain and medication score (PAMS), calculated as a combined pain/medication score, every 6 h as (VAS+ketoprofendose100)÷2; (2) total surgical duration in min; (3) calculated blood loss (CBL), derived as BVM × %BVΔ, where BVM is maternal blood volume calculated using Nadler’s formula [13] and %BVΔ is percent change (i.e., loss) of blood calculated using Brecher’s formula [13]; (4) maternal autonomy, calculated as a last of the postoperative times to spontaneous urination, standing, or first meal in hours—whichever came last; and (5) time to discharge in days. Newborn outcomes measures were: (1) appearance, pulse, grimace, activity, and respiration (APGAR) score at 1, 3, 5, and 10 min; (2) acid-base balance/eucapnic pH [14,15]; and (3) rate of hospitalization.

Statistical analysis

Sample size calculation was based on the PMPS. The effect of FAUCS was considered important if the difference in PMPS between groups was ≥ 30%, using a t-test. To achieve 80% power with an α = 0.05, it was anticipated that 45 patients in each group were required.

Data were analyzed by generalized linear models for which Nagelkerke’s pseudo-R2 was calculated. Combined pain/medication score was analyzed as a repeated measure with generalized mixed-level linear models testing “technique + time” and “technique + time + (technique × time)”, with individual patient as a random effect. Maternal autonomy was analyzed by a Cox proportional hazard model with patient as a gamma-distributed frailty term. Surgical duration, CBL, days to discharge, and eucapnic pH were analyzed as continuous variables using generalized linear models. Incidence of neonate hospitalization was analyzed using a logistic generalized linear model. The APGAR score was analyzed using cumulative link mixed models.

Results

Of the 487 women who underwent a CS during the study period, 169 were planned and were assessed for eligibility. One hundred women were randomized into the FAUCS or MLCS group. After randomization, all patients completed the study and were included in the analysis (Fig 1). There were no significant differences between groups in women’s epidemiological or obstetric characteristics (Table 1).

Fig 1. CONSORT 2010 flow diagram.

Fig 1

Table 1. Patient characteristics.

Characteristic MLCS groupa FAUCS groupa Test statisticb p-valuec R2d Raw p-value
Weight (kg) 82.95 ±1.99 79.52 ± 1.69 1.741 (1, 98) 1.000 0.018 0.190
Height (m) 1.61 ± 0.01 1.62 ± 0.01 0.065 (1, 98) 1.000 0.000 0.799
BMI 31.79 ± 0.61 30.42 ± 0.55 2.758 (1, 98) 0.900 0.027 0.100
Age (years) 33.86 ± 0.75 32.80 ± 0.77 0.975 (1, 98) 1.000 0.010 0.326
Gestation (weeks) 39.08 ± 0.10 39.14 ± 0.10 0.185 (1, 98) 1.000 0.002 0.668
Pre-operative hematocrit 33.82 ± 0.49 33.68 ± 0.45 0.040 (1, 98) 1.000 0.000 0.841
Gravidity 2.5 ± 0.5 2.5 ± -2 0.231 (1) 1.000 0.018 0.631
Parity 2 ± 1/0 2 ± -1/2 1.730 (1) 1.000 0.002 0.188
Prior CS 1 ± 1/0 1 ± -0.25/0 0.628 (2) 1.000 0.007 0.730

aMean ± Standard error of mean (SEM) for weight, height, body mass index (BMI), age, gestation, and hematocrit; Median ± 75th/25th percentiles for gravidity, parity, and prior CS.

bF (dfnumerator, dfdenominator) for weight, height, BMI, age, gestation, and hematocrit; likelihood ratio χ2 (df) for gravidity, parity, and prior CS.

cHolm-adjusted for family-wise error rate, nine simultaneous tests.

dNagelkerke’s pseudo R2.

FAUCS could be performed for all patients who previously underwent MLCS; in these cases, tissues were mostly non-cicatricial for the left paravesical extraperitoneal approach. No patients had previously undergone FAUCS prior to this study. No cases needed to be excluded intraoperatively.

Overall, postoperative pain was significantly higher in MLCS patients (PMPS [first–third quartile], 2.93 [2.46–3.75]) than in FAUCS patients (1.87 [1.04–2.41]; p < 0.001). However, the effects of technique and time and their interaction were all significant (p < 0.001, p < 0.001, and p = 0.001, respectively). Specifically, 6 h after surgery, the PAMS was 33% lower for FAUCS patients than for MLCS patients (Fig 2). Although PAMS for both groups converged over time, scores remained lower for FAUCS patients than for MLCS patients at each time point (Table 2). Also, FAUCS allowed a faster return to autonomy, with 94% of FAUCS patients attaining autonomy by 12 h compared with 4% of MLCS patients.

Fig 2. General linear model analysis of PAMS score at selected time points post-CS.

Fig 2

Hypothesis tested was whether overall PAMS differed between FAUCS and MLCS (Technique variable), PAMS would decrease over time (Time variable), and the rates of decrease (interaction) would differ between FAUCS and MLCS. Data are shown as mean ± SEM. Dashed lines represent model predictions for fixed effects (technique, time, and technique × time). Effect of Technique χ2 (df) = 46,38 (1,94); p < 0.001; R2 0.192; raw p < 0.001. Effect of Time χ2 (df) = 70,57 (2,94); p < 0.001; R2 .144; raw p < 0.001. Effect of Technique x Time χ2 (df) = 13,46 (2,94); p = 0.011; R2 0.037; raw p = 0.001.

Table 2. PAMS (mean ± SEM) at various time points post-CS.

Time (h) MLCS group FAUCS group Mean difference
6 7.00 ± 0.14 2.28 ± 0.33 4.72 ± 0.46
12 4.23 ± 0.42 2.10 ± 0.23 2.13 ± 0.32
18 3.24 ± 0.40 1.82 ± 0.27 1.42 ± 0.39
24 2.56 ± 0.36 1.10 ± 0.18 1.46 ± 0.26

All patients, regardless of group, attained autonomy by 24 h post-delivery (Fig 3). However, FAUCS patients recovered more rapidly than MLCS patients (p < 0.001), with 94% of FAUCS patients attaining autonomy by 12 h compared with 4% of MLCS patients (Table 3). MLCS patients were discharged in 1.88 ± 0.05 (mean ± SEM) days versus 1.18 ± 0.07 days for FAUCS patients (p < 0.001).

Fig 3. Cox proportional hazards model analysis of percentage of patients exhibiting autonomy at selected time points post-CS.

Fig 3

Hypothesis tested was that FAUCS would result in more rapid gain of the “autonomy” measure. Effect of Technique χ2 (df) = 625 (1); p < 0.001; R2 0.174; raw p < 0.001. Effect of frailty (patient) χ2 (df) = 490 (1); p < 0.001; R2 .758; raw p < 0.001.

Table 3. Percentage of patients exhibiting autonomy at various time points.

Time (h) MLCS group FAUCS group
2 0% 2%
6 0% 44%
12 4% 94%
18 28% 98%
24 100% 100%

Total surgical duration (38.38 ± 2.24 vs. 43.31 ± 7.34 min, p = 0.414) and CBL (520 ± 58 vs. 536 ± 50 ml, p = 0.724) were similar in MLCS and FAUCS patients, respectively. The hypothesis tested was that the durations would differ. Instrument assistance using forceps or spatulas was necessary in 84% of FAUCS procedures (p < 0.001). The hypothesis tested was that FAUCS would result in increased instrument assistance, as FAUCS incisions are smaller and instrument assistance usually described as part of the technique.

Newborn outcomes did not differ by surgical procedure. Visual inspection after a cumulative link mixed model analysis of APGAR scores appeared to show a slightly beneficial effect of FAUCS, which was associated with an APGAR score of 10 at 1 min. However, the effect size for this difference was small (Cramer’s V = 0.123 at 1 min) and grew smaller over time (Cramer’s V = 0.096, 0.060, and 0.000 at 3, 5, and 10 min, respectively). Eucapnic pH and frequency of hospitalization were similar in both groups (p = 0.714 and p = 1.000, respectively).

Discussion

We found that the FAUCS technique described by Ami et al. [9] reduces postoperative pain without increasing intra- or postoperative complications compared with MLCS in elective conditions. FAUCS also enhanced women’s autonomy after surgery, thus shortening their hospital stay.

The sample size assumptions were realized in this clinical trial, with an initial hypothesis of 30% reduction of PMPS, and an effective 36,17% of PMPS reduction observed.

For both pain and autonomy measures, the advantageous effect of FAUCS over MLCS was higher at earlier time points after surgery. From both patient and medical management standpoints, these are critical outcomes.

Given that the rate of planned CS is increasing in many countries, obstetric teams are working to enhance women’s recovery and reduce their length of hospital stay [10]. The most common steps for enhancing recovery after surgery are early oral intake, early mobilization, early removal of catheters, patient advice and information, and regular postoperative analgesia. A previous study has shown that an enhanced recovery program for women undergoing planned CS increases the proportion of women discharged on day 1 from 1.6% to 25.2% [16]. In most settings, hospitalization after a CS delivery is 3–4 days, which could make it difficult to envision women being discharged 24 h after surgery. However, this was achieved in the previous study using adequate analgesia and follow-up at home without making any improvements to the surgical technique. In the present study, improvements in women’s outcomes after CS were achieved by the surgical technique itself. Specifically, 86% of women who underwent FAUCS were discharged on day 1. It could be speculated that immediate mobilization after FAUCS could help prevent venous thromboembolism and promote early mother-baby bonding. Furthermore, the absence of peritoneal cavity opening allows earlier oral food intake. All of these beneficial short-term outcomes could also improve long-term outcomes, such as preservation of future fertility, by preventing intraperitoneal adhesions.

The FAUCS technique involves multiple innovations that might hinder its diffusion. However, each of these innovations has the potential to bring about benefits. First, left paramedian incision could benefit from the natural mechanical behavior of the abdominal wall. The stiffest structures, specifically the aponeuroses and linea alba, are those that perform the most work in the abdomen. Thus, the linea alba is the most important unit contributing to the mechanical stability of the abdominal wall [17]. Greater compliance of the linea alba, strain on the intact abdominal wall, and stiffness of the rectus sheath and umbilical fascia all exist when tissues are loaded in the longitudinal direction compared with the transverse direction [18]. Additionally, greater stress is placed on the linea alba when it is loaded in the transverse direction compared with that in the longitudinal direction [18]. The lateral paramedian incision is slightly more time-consuming to perform but results in a significantly lower incidence of incisional hernia [19]. When a vertical abdominal incision is being considered, the lateral paramedian should be the incision of choice [19]. In our study, a paramedian incision contributed to women’s quick recovery after CS. Further studies are needed to confirm this impact on mid- and long-term maternal autonomy.

Extraperitoneal CS is a method of surgically delivering a baby through an incision in the lower uterine segment without entering the peritoneal cavity, given keeping the peritoneal cavity intact reduces the risk of adhesions, postoperative ileus, and future infertility related to surgery [20]. In the FAUCS technique, the uterus is approached through the paravesical space, which can allow the earlier return of bowel function, as evidenced by the higher autonomy scores among FAUCS patients than among MLCS patients. Similar results are reported in randomized trials, which show that bowel function returns at an average of 8 ± 4 h in extraperitoneal CS compared with 13 ± 4 h in transperitoneal CS [20]. Extraperitoneal CS also reduces the use of intravenous fluids and analgesics without increasing surgical complications [4,9,20]. In our study, we observed no complications in either group. Since the implementation of FAUCS in our study unit [4], we have experienced three bladder injuries out of 200 cases. In a retrospective study introducing the FAUCS technique [9], 11 out of 3,441 cases (0.3%) involved bladder injury. However, bladder injuries during CS are not specific to the extraperitoneal approach and have an overall incidence of 0.44% [21].

During FAUCS, the combination of a horizontal skin incision, paramedian vertical aponeurotic opening, and extraperitoneal approach leads to a relatively small extraction field [9]. Consequently, instruments are often used to facilitate fetal extraction [4,9], as was done for 84% of our FAUCS patients. However, this appeared to have no impact on neonatal outcomes, given fetal blood eucapnic pH and the frequency of neonatal hospitalization did not differ between FAUCS and MLCS.

We recommend some tips for reducing extraction time while performing FAUCS, such as: (1) opening the anterior rectus sheath with sufficient width up and down; (2) reclining the left rectus abdominis muscle correctly to the left; and (3) involving the mother in the process by having her control her breathing [4,22] during the use of small guiding instruments (e.g., Wrigley forceps or Teissier spatulas) [23] which allows to perform smaller incisions. This instrument assistance is usually very easily and gently performed, while there is no bony obstacle to the exit of the newborn, but only soft tissues around.

Uterine incision closure is the most important factor contributing to good healing and preventing future CS-related complications. With continuous single-layer uterine closure, uterine incisional defects occur in 20%-60% of cases [24]. It is reasonable to believe that uterine scarring defects reflect poor or incomplete healing of part of the hysterotomy. The mechanism of this defective healing could be the mechanical tension of the lower uterine segment, which might impair blood perfusion and oxygenation of healing tissues. To reduce mechanical tension in the lower uterine segment, purse-string suturing has been used to remove myomas during CS [25]. Purse-string suture of the uterine incision provides good control of bleeding and decreases the length of the uterine wound while increasing its thickness [9]. Unlike the Turan technique described in 2015 [24], FAUCS uterine closure uses a double-layer purse-string closure. A previous study has shown that with the purse-string closure technique, uterine incision length is shorter (3.7 cm vs. 8.5 cm) and uterine scar defect frequency is lower (23.5% [12/51] vs. 60% [39/65]) than that for the traditional double-layer uterine closure technique [9]. The high frequency of uterine incision defects in the previous study might have been because the incision site was examined only 6 weeks after surgery. A second study with the same study population is currently in progress to evaluate purse-string closure 6 months after surgery (NCT03930134).

In the present study, total surgical duration was similar between groups (38.38 ± 2.24 min for MLCS vs. 43.31 ± 7.34 min for FAUCS; p = 0.414), consistent with our observation of no difference in CBL. However, during the FAUCS learning curve [4], surgical duration is longer for the FAUCS technique than for the MLCS technique (50 [40–60] vs. 35 [30–40] min, respectively, p < 0.001) [4].

This study has potentially significant limitations. In particular, the anesthesia protocols for the two techniques differed. Thus, the absence of the adverse effects of morphine in the FAUCS group (e.g., nausea, delayed transit, urinary sphincter retention) could have led to improved outcomes. Morphine in the epidural has long been considered necessary in our anesthesiology department as part of the early post-surgery rehabilitation protocol, given it effectively reduces pain on the first day and facilitates early mobilization. However, we excluded it from the FAUCS protocol because we have found that this surgical procedure allows early mobility without a high degree of pain, with previous studies also supporting its exclusion [4,9]. While it might be tempting to “fold” potential opiate-specific effects into any comparison against MLCS, we must admit that an unknown and potentially important proportion of differences between MLCS and FAUCS is actually due to morphine. However, such a comparison would require performing MLCS without morphine, which requires particularly ethically sensitive research specific to withholding anesthesia. Such work could be more appropriate to a multi-center study.

In conclusion, our findings indicate that FAUCS reduces pain and enhances recovery compared with MLCS. Therefore, we conclude that FAUCS is a highly desirable method to use in cases of planned CS, is superior to MLCS, and should be implemented on a widespread basis.

Supporting information

S1 Checklist. Consort checklist.

(DOC)

S1 Dataset

(XLSX)

S1 File. Original trial study protocol.

(DOCX)

S2 File. Translation trial study protocol.

(PDF)

Acknowledgments

The authors thank Israel Hendler (reviewing and editing the article) and Sivan Navot and Samy Chouial (diffusion of the results) who have made valuable contributions in preparation of this article.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Dodd JM, Anderson ER, Gates S, Grivell RM. Surgical techniques for uterine incision and uterine closure at the time of caesarean section. Cochrane Database Syst Rev. 2014; CD004732 10.1002/14651858.CD004732.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kulas T, Bursac D, Zegarac Z, Planinic-Rados G, Hrgovic Z. New Views on Cesarean Section, its Possible Complications and Long-Term Consequences for Children’s Health. Med Arch. 2013;67: 460–463. 10.5455/medarh.2013.67.460-463 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Katsulov A, Nedialkov K, Koleva Z, Iankov M, Tashkov B, Iotov T, et al. [The Joel-Cohen (Misgav Ladach) method—a new surgical technic for cesarean section and gynecological laparotomy]. Akush Ginekol (Sofiia). 2000;39: 10–13. [PubMed] [Google Scholar]
  • 4.Dimassi K, Ami O, Fauck D, Simon B, Velemir L, Triki A. French ambulatory cesarean: Mother and newborn safety. Int J Gynaecol Obstet. 2020;148: 198–204. 10.1002/ijgo.13013 [DOI] [PubMed] [Google Scholar]
  • 5.Panda S, Begley C, Daly D. Clinicians’ views of factors influencing decision-making for caesarean section: A systematic review and metasynthesis of qualitative, quantitative and mixed methods studies. PLoS ONE. 2018;13: e0200941 10.1371/journal.pone.0200941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ami O, Maran JC, Gabor P, Whitacre EB, Musset D, Dubray C, et al. Three-dimensional magnetic resonance imaging of fetal head molding and brain shape changes during the second stage of labor. PLOS ONE. 2019;14: e0215721 10.1371/journal.pone.0215721 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tappauf C, Schest E, Reif P, Lang U, Tamussino K, Schoell W. Extraperitoneal versus transperitoneal cesarean section: a prospective randomized comparison of surgical morbidity. Am J Obstet Gynecol. 2013;209: 338.e1–8. 10.1016/j.ajog.2013.05.057 [DOI] [PubMed] [Google Scholar]
  • 8.S BD, J C. Extraperitoneal versus transperitoneal cesarean section in surgical morbidity in a tertiary care centre. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2017;6: 3397–3399. 10.18203/2320-1770.ijrcog20173450 [DOI] [Google Scholar]
  • 9.Ami O, Fauck M, Simon B, Benhamou R, Caraco J-J, Velemir L, et al. The French Ambulatory Cesarean Section: Technique and Interest. International Journal of Gynecology & Clinical Practices. 2017;4: 1–6. [Google Scholar]
  • 10.Corso E, Hind D, Beever D, Fuller G, Wilson MJ, Wrench IJ, et al. Enhanced recovery after elective caesarean: a rapid review of clinical protocols, and an umbrella review of systematic reviews. BMC Pregnancy and Childbirth. 2017;17: 91 10.1186/s12884-017-1265-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kendall MG, Smith BB. Tables of random sampling numbers. Cambridge [England]: U.P; 1961. Available: https://trove.nla.gov.au/version/27753808 [Google Scholar]
  • 12.McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18: 1007–1019. 10.1017/s0033291700009934 [DOI] [PubMed] [Google Scholar]
  • 13.Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997;37: 1070–1074. 10.1046/j.1537-2995.1997.371098016448.x [DOI] [PubMed] [Google Scholar]
  • 14.Racinet C, Richalet G, Corne C, Faure P, Peresse J-F, Leverve X. Diagnostic de l’acidose métabolique à la naissance par la détermination du pH eucapnique. Gynécologie Obstétrique & Fertilité. 2013;41: 485–492. 10.1016/j.gyobfe.2013.07.020 [DOI] [PubMed] [Google Scholar]
  • 15.Racinet C, Ouellet P, Charles F, Daboval T. Neonatal metabolic acidosis at birth: In search of a reliable marker. Gynecol Obstet Fertil. 2016;44: 357–362. 10.1016/j.gyobfe.2016.04.005 [DOI] [PubMed] [Google Scholar]
  • 16.Wrench IJ, Allison A, Galimberti A, Radley S, Wilson MJ. Introduction of enhanced recovery for elective caesarean section enabling next day discharge: a tertiary centre experience. Int J Obstet Anesth. 2015;24: 124–130. 10.1016/j.ijoa.2015.01.003 [DOI] [PubMed] [Google Scholar]
  • 17.Hernández-Gascón B, Mena A, Peña E, Pascual G, Bellón JM, Calvo B. Understanding the passive mechanical behavior of the human abdominal wall. Ann Biomed Eng. 2013;41: 433–444. 10.1007/s10439-012-0672-7 [DOI] [PubMed] [Google Scholar]
  • 18.Deeken CR, Lake SP. Mechanical properties of the abdominal wall and biomaterials utilized for hernia repair. Journal of the Mechanical Behavior of Biomedical Materials. 2017;74: 411–427. 10.1016/j.jmbbm.2017.05.008 [DOI] [PubMed] [Google Scholar]
  • 19.Guillou PJ, Hall TJ, Donaldson DR, Broughton AC, Brennan TG. Vertical abdominal incisions—a choice? Br J Surg. 1980;67: 395–399. 10.1002/bjs.1800670605 [DOI] [PubMed] [Google Scholar]
  • 20.Yapca OE, Topdagi YE, Al RA. Fetus delivery time in extraperitoneal versus transperitoneal cesarean section: a randomized trial. J Matern Fetal Neonatal Med. 2018; 1–7. 10.1080/14767058.2018.1499718 [DOI] [PubMed] [Google Scholar]
  • 21.Perkins RP. Role of extraperitoneal cesarean section. Clin Obstet Gynecol. 1980;23: 583–599. 10.1097/00003081-198006000-00026 [DOI] [PubMed] [Google Scholar]
  • 22.Reeducation thoraco-abdomino pelvienne par le concept abdo-mg—Luc Guillarme—Frison Roche—Grand format—Sauramps. Available: https://www.sauramps.com/livre/9782876715455-reeducation-thoraco-abdomino-pelvienne-par-le-concept-abdo-mg-luc-guillarme/
  • 23.Simon-Toulza C, Parant O. [Spatulas: description, obstetrical mechanics, indications and contra-indications]. J Gynecol Obstet Biol Reprod (Paris). 2008;37 Suppl 8: S222–230. 10.1016/S0368-2315(08)74760-4 [DOI] [PubMed] [Google Scholar]
  • 24.Turan C, Büyükbayrak EE, Yilmaz AO, Karsidag YK, Pirimoglu M. Purse-string double-layer closure: a novel technique for repairing the uterine incision during cesarean section. J Obstet Gynaecol Res. 2015;41: 565–574. 10.1111/jog.12593 [DOI] [PubMed] [Google Scholar]
  • 25.Lee J-H, Cho D-H. Myomectomy using purse-string suture during cesarean section. Arch Gynecol Obstet. 2011;283: 35–37. 10.1007/s00404-010-1760-2 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Georg M Schmölzer

30 Oct 2020

PONE-D-20-27208

The extraperitoneal French AmbUlatory cesarean section technique leads to superior maternal outcomes compared with the intraperitoneal Misgav Ladach technique: A prospective randomized controlled trial

PLOS ONE

Dear Dr. Kaouther Dimassi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by December 20 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Georg M. Schmölzer

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study.

As per the journal’s editorial policy, please include in the Methods section of your paper:

1) your reasons for your delay in registering this study (after enrolment of participants started);

2) confirmation that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered”.

Please also ensure you report the date at which the ethics committee approved the study as well as the complete date range for patient recruitment and follow-up in the Methods section of your manuscript.

3.  Thank you for including your ethics statement:  "ethics committee mongi slim university hospital , la marsa tunisia

approval number 05/2018

written consent"

Please amend your current ethics statement to confirm that your named institutional review board or ethics committee specifically approved this study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

4. Thank you for stating the following in the Competing Interests section:

"NO authors have competing interests"

We note that one or more of the authors are employed by a commercial company: Ramsay Healthcare France.

4.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

4.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors present the results of a single center randomized trial of two different cesarean delivery techniques to determine if the French AmbUlatory cesarean (FAUCS) technique resulted in significantly lower postoperative mean pain scores than a more standard technique used at their hospital, the Misgav Ladach (MLCS) approach. Other outcomes included a combined pain and medication score, total surgical duration, calculated blood loss, maternal autonomy which included measures of time to urination, standing and eating meals, and length of stay. One of two surgeons performed all procedures. Unfortunately, the anesthetic techniques differed between the two groups. The authors conclude that the FAUCS technique “can reduce postoperative pain and accelerate recovery” when compared to the MLCS approach.

Questions and comments for the authors.

1. Inclusion/Exclusion criteria. The general summary statement on the Clinicaltrials.gov site states that women at 36 weeks’ gestation and greater were eligible. On the Clinicaltrials.gov site there is also a link to PDF titled, “Study Protocol and Statistical Analysis Plan”. In this document, the inclusion criteria section states that women 37 weeks’ and greater were eligible. Next, the manuscript does not specifically state the gestational age at which women were eligible. Please add to the manuscript the gestational age inclusion criteria and clarify the discrepancy between the summary on the Clinicaltrials.gov site and that in above-referenced study protocol PDF, which is a link on the CT.gov site. The manuscript also does not list the age that women had to be in order to be eligible (CT.gov site states 18-48 years).

2. Randomization scheme. The Materials and Methods section of the manuscript (page 5) states that “The two comparison groups were generated using simple randomization, with an equal allocation ratio, by referring to Kendall and Smith’s Table of Random Sampling Numbers [11]”. I went to the referenced web site and the text book was not available on the listed link. Please provide more explanation on the randomization scheme. What were the block sizes? Were blocks used or was the randomization just alternating group assignments. This is important because if blocks were not used and the randomization was just simple alternating numbers, the providers could guess which technique was next and it is possible then that the subject could have been informed of the allocation group.

3. Blinding. The second paragraph of page 5 states that you performed an “unblinded randomized clinical trial” but then on page 6, in the first paragraph you state “participants, residents involved in patient care, and all investigators were blinded”. These two statements seem contradictory. I appreciate that the surgical team cannot be blinded to the cesarean but then you state that “all investigators were blinded”. If the surgeons are co-authors on the manuscript, then I would consider them as investigators. Next, were residents who performed the post-operative care not present or scrubbed for the surgery? Please clarify the statements about blinding. I worry greatly that patients could have discovered which group assignment they were in and if they then also knew that FAUCS was the intervention being tested, that they would then want to report improved pain scores.

4. Anesthetic plan. Each group received a different anesthetic regimen. You acknowledge this limitation (page 16), but I believe this to be a significant weakness in your study. The anesthetic regimens may be driving your outcomes rather than the surgical procedure. By having different anesthetic regimens between the two groups, you lose the benefit of performing a randomized trial that attempts to test the difference between two surgical techniques. With this design, it is impossible to know if the different surgical techniques are driving the findings, or the different anesthetic techniques. This limitation needs to be highlighted throughout the text, including any concluding statements in the Abstract and Discussion (and title) sections which state that the FACUS resulted in improved postoperative pain.

5. Surgical techniques. Neither the MLCS nor the FAUCS techniques are commonly used in the United States. You provide some references to the techniques and briefly describe them but my preference is that more information be provided on these techniques. Can you work with the Academic Editor on this? Maybe you could include illustrations of the two techniques as Supplemental material. This added information would help obstetricians in the United States better understand the two techniques. Most obstetricians in the US use either a Pfannenstiel (with lateral rectus sheath fascial incisions) or a Joel-Cohen technique.

6. One of the secondary outcomes was listed as “combined pain/medical score”. Which analgesic agent was used for the combined pain/medical score calculation? Earlier in the manuscript, you state that your standard postoperative analgesic plan was intra-rectal ketoprofen and then intravenous paracetamol as second line. Did you just use the ketoprofen medication dose in the calculation used for this secondary outcome? Please clarify.

7. The title states that the FAUCS “leads to superior maternal outcomes”. I would clarify this statement and make it more specific; i.e. improved pain scores. Also see my concerns outlined in #4.

8. You state that your primary outcome is a mean of the five VAS scores performed at postoperative time points, H0, H6, H12, H18 and H24. These five time points were never explicitly defined. I appreciate that they were performed every six hours over the course of 24 hours but when did they start? What is H0? Please clarify.

9. Table 2 and Figure 2 provide mean VAS scores at each of the five time points. The y-axis of the figure and the table legend both use the abbreviation “PMPS”. This is technically not correct. You define the PMPS as the average of the five time points while the figure and table provide the mean of each of the individual VAS scores at each time point. Please clarify and adjust the Figure axes and Table legend to clarify that you are presenting mean VAS scores at each time point and not your defined PMPS.

10. Please provide p-values in Tables 2 and 3 so the reader can determine if the differences in mean VAS scores (Table 2) and autonomy scores (Table 3) are significantly different at each time point. This is particular important as you claim that the FAUCS results in improved pain and autonomy.

11. Table 1 lists Test statistic values, p-values, R2 values and raw p-values. These can all be excluded from the table given that your performed a randomized trial. The Academic Editor can clarify if the journal requires these values.

12. The first full paragraph of the Page 10 (Results section) provides the differences in “postoperative pain” between the two groups. Is this your PMPS score? If so, please clarify.

13. I am confused about the secondary outcome that is labeled “maternal autonomy”. You attempt to define this outcome in the ‘Study Outcomes’ paragraph on page 7 but the definition is still not clear. You state that maternal autonomy was “calculated as a summation of postoperative times to spontaneous urination, standing, or first meal in hours”. Please provide more information on how this variable was calculated. Was it the amount of time from the conclusion of the surgery to any one of those three outcomes? The inclusion of the word “or” suggests that it was the time to any one of the three but you also use the word ‘summation’, which suggests it was the total time to all three. Was the outcome; autonomy = (time from end of surgery to urination) + (time from end of surgery to unassisted standing) + (time from end of surgery to first meal)? Were foley catheters removed at the same duration of time following surgery for all subjects? If not, the variation in when the catheters were removed could affect this outcome rather than the surgical intervention. The delivery of food trays could also be varied based on what time of day the surgery was performed. Since you don’t feed women until they pass flatus, why did you use eating as the outcome variable rather than passing flatus?

14. The last sentence on page 11 states, “Instrument assistance was necessary in 84% of FAUCS procedures (p<0.001)”. What instruments are you referring to? Next, what is the p-value comparing this outcome to? Is it for the use of instruments in the MLCS group?

15. The second paragraph of the Discussion section refers to better overall birth experience and lower financial costs. Neither of these outcomes were studied, thus I would suggest that these claims are removed from the manuscript.

16. I may have missed it, but I did not see that you reported the 'combined pain/medication score' outcome data that was a planned secondary outcome.

17. The third paragraph of the Discussion includes a statement, “We found that FAUCS was so effective at reducing surgical pain that early rehabilitation depended more on preserved maternal autonomy than on painkillers and protocols”. I do not understand this statement. Next, given that the two groups received different anesthetic protocols, you do not know if the differences in postoperative pain scores that were seen were due to the surgical technique or the anesthetic technique.

18. CONSORT. Please state that the full protocol is available on the Clinicaltrials.gov site. See my concerns above about randomization and blindings.

Reviewer #2: This is the report of a randomized clinical trial of Cesarean techniques (I think Cesarean should be capitalized throughout, incidentally). The primary outcome is a VAS composite score. The authors need to reference their score functions, or at least explain why they are appropriate. The randomization procedure is described, statistical analysis is sophisticated with longitudinal and survival models, and limitations of the study are clearly enumerated. The study statistician uses Holm's method to adjust for multiplicities. From a statistical standpoint, the authors are to be congratulated. There are two glaring omissions that would be useful to correct in a revision:

1. Sample size is not really described. 30% of what? What are the assumptions? Is this based on the actual analysis technique in the study, or just a simple t-test? In the discussion, the authors should clearly point out if the sample size assumptions were actually realized in the clinical trial so we can figure out if the study was over- or under- powered.

2. Lots of great regression models, and not a single word about assumptions of the model, or whether these assumptions were tested or met.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 22;16(1):e0245645. doi: 10.1371/journal.pone.0245645.r003

Author response to Decision Letter 0


22 Dec 2020

Dear Editor,

Thank you for considering our paper for publication in PlosOne.

You will find below our responses to each point raised by the academic editor and reviewer(s).

Best regards

Academic Editor’s comments

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

We have done so

2. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study.

As per the journal’s editorial policy, please include in the Methods section of your paper:

1) your reasons for your delay in registering this study (after enrolment of participants started)

All the protocols were originally written in French. The submission to clinicaltrials.gov needed translation of our protocol and the review process went late because of administrative delay in our hospital and unavailability of some actors participating in the consensus of decisions regarding the protocol. We decided not to delay the research, and the manuscript makes it plain that study approval by the ethics committee was in March of 2018 and procedures began in August of 2018. Registration at "clinicaltrials.gov" is not mandated by Tunisian law, which covered all legal aspects of this study.

2) confirmation that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered”.

Please also ensure you report the date at which the ethics committee approved the study as well as the complete date range for patient recruitment and follow-up in the Methods section of your manuscript.

We have done so

3. Thank you for including your ethics statement: "ethics committee mongi slim university hospital , la marsa tunisia

approval number 05/2018

written consent"

Please amend your current ethics statement to confirm that your named institutional review board or ethics committee specifically approved this study.

We have done so

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

4. Thank you for stating the following in the Competing Interests section:

"NO authors have competing interests"

We note that one or more of the authors are employed by a commercial company: Ramsay Healthcare France.

The Ramsay Healthcare Group is a private hospital group. It is not a simple commercial company, but a company owning several private hospitals in Europe. The doctors who work in these hospitals are principally not salaried employees but liberal doctors, and they are not necessarily financed by the private hospital for their research work. In this case, none of the doctors received any funding from Ramsay Healthcare.

4.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

None of the authors are salaried of Ramsay Healthcare, but doctors affiliated with Ramsay Healthcare hospitals work as liberal doctors and did not receive any funding for this research protocol.

4.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

None of the authors are salaried of Ramsay Healthcare, but doctors affiliated with Ramsay Healthcare hospitals work as liberal doctors and did not receive any funding for this research protocol nor have any competing interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

We included both an updated Funding Statement and Competing Interests Statement in our cover letter, thank you for changing the online submission form on our behalf.

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

Upon review of these statements, we agree that our data has been sufficiently anonymized and provide it to plosone for unrestricted public access

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

We have done so.

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 1

Georg M Schmölzer

6 Jan 2021

The extraperitoneal French AmbUlatory cesarean section technique leads to improved pain scores and a faster maternal autonomy compared with the intraperitoneal Misgav Ladach technique: A prospective randomized controlled trial

PONE-D-20-27208R1

Dear Dr. Kaouther Dimassi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Georg M. Schmölzer

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Georg M Schmölzer

11 Jan 2021

PONE-D-20-27208R1

The extraperitoneal French AmbUlatory cesarean section technique leads to improved pain scores and a faster maternal autonomy compared with the intraperitoneal Misgav Ladach technique: A prospective randomized controlled trial

Dear Dr. dimassi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Georg M. Schmölzer

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. Consort checklist.

    (DOC)

    S1 Dataset

    (XLSX)

    S1 File. Original trial study protocol.

    (DOCX)

    S2 File. Translation trial study protocol.

    (PDF)

    Attachment

    Submitted filename: response to comments .docx

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES